Yzy Biopharmaceutical

Wuhan YZY Biopharmaceutical Co., Ltd. is a biopharmaceutical company specializing in tumor immunotherapy, focusing on the research and development and industrialization of bispecific antibody drugs. Since its establishment in July 2010 and its entry into the Wuhan National Bio-industry Base - Optics Valley Biopharmaceutical Park, the company has a registered capital of 141.42 million RMB and has invested over 250 million RMB in research and development. In January 2018, the company reached a strategic cooperation with CSPC Group, a leading domestic pharmaceutical enterprise, to jointly advance the construction of the R&D pipeline and clinical research, creating a new landscape for tumor immunotherapy in China. Bispecific antibody drugs are the core R&D direction of next-generation antibody drugs, with broad therapeutic prospects in major diseases such as oncology, immunology, inflammation, cardiovascular, and infection. Based on its independently innovative YBODY® platform technology, YZY Biopharmaceutical has successfully developed a series of bispecific antibody products with advanced technology, high purity, and good long-term stability. Multiple products have received support from the national "Twelfth Five-Year Plan" and "Thirteenth Five-Year Plan" major new drug creation projects. Among them, two varieties for the treatment of gastric cancer and breast cancer, and for the treatment of advanced cancerous ascites, have been the first in China to obtain clinical trial approvals and conduct clinical research, while another 10 varieties are at different preclinical research stages. Regarding core technologies and products, the company has filed 38 invention patent applications and obtained 9 authorizations (including 4 US authorized patents). YZY Biopharmaceutical, with the mission of "tracing the origin of life and decoding tumors" and with innovative R&D at its core, has established a complete antibody drug development industry chain, encompassing antibody engineering construction and screening, cell line development and small-scale process, pilot-scale scale-up, protein drug analysis quality control, and production of clinical drugs. The company has a research and development building of 4,000 square meters and two GMP-compliant 250L pilot production lines. The company's core technical and management teams have international first-class experience in innovative drug R&D. The team includes three overseas returnees as academic leaders, nearly 80 full-time R&D personnel, with over 50% holding doctoral degrees, and many experts have been selected for the Hubei Province "Hundred Talents Plan", Wuhan "3551 Optics Valley Talent Plan", National Foreign Experts Recruitment Plan, and Huanghe Friendship Award. As a leading enterprise in the development of bispecific antibody drugs in China, YZY Biopharmaceutical will continue to expand the depth and speed of innovative technology and product development, accelerate the transformation of technological achievements, and vigorously promote the company's internationalization process. The company plans to achieve an IPO listing in early 2021, as well as product launch and annual sales of 1 billion RMB, while fully advancing the development of its internationally innovative drugs in markets such as the United States, aiming for overseas listing before 2023. Interested candidates are requested to send their resumes in plain text format to the company email address. (Email subject format: XXX applying for XXX position). We will contact you as soon as possible and arrange an interview time. The company is currently recruiting core talents including senior immunologists, tumor biologists, and clinical experts worldwide, and looks forward to creating new value in the field of tumor immunotherapy together with you!